Genomic medicine and thrombotic risk: Who, when, how and why?
- 4 January 2006
- journal article
- review article
- Published by Elsevier BV in International Journal of Cardiology
- Vol. 106 (1), 3-9
- https://doi.org/10.1016/j.ijcard.2004.11.038
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Endothelial Nitric Oxide Synthase Genotype and Ischemic Heart DiseaseCirculation, 2004
- Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studiesAmerican Heart Journal, 2003
- From Vulnerable Plaque to Vulnerable PatientCirculation, 2003
- Management of thrombophiliaJournal of Thrombosis and Haemostasis, 2003
- What does “A gene for heart disease” mean? A focus group study of public understandings of genetic risk factorsAmerican Journal of Medical Genetics Part A, 2003
- The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin MutationThe New England Journal of Medicine, 1999
- Apolipoprotein E Alleles and Risk of Coronary DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Deficiency of protein C in congenital thrombotic disease.JCI Insight, 1981